# Cybin Inc. (HELP)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Price:** $3.87 (-1.28%)

> Cybin Inc. is a clinical-stage neuropsychiatry company dedicated to developing psychedelic-based therapeutics to address unmet needs in mental health treatment. Its lead candidate, CYB003, a proprietary deuterated psilocybin analog, is advancing in phase 3 clinical trials for major depressive disorder, including the multinational EMBRACE study approved in Australia and Europe. CYB004, a deuterated DMT molecule, is in phase 2 trials for generalized anxiety disorder, with enrollment recently completed. The pipeline also features investigational compounds like SPL028, an injectable deuterated DMT that completed phase 1 trials, SPL026 for MDD, and CYB005, a phenethylamine derivative in preclinical stages targeting neuroinflammation and central nervous system disorders. Headquartered in Toronto, Ontario, with approximately 50 employees, Cybin Inc. collaborates with partners such as TMS Neurohealth Centers, Kernel, and Segal Trials to advance its research. Founded in 2016 and led by CEO Eric So, the company plays a pioneering role in the emerging field of psychedelic medicine within the biopharmaceutical sector, focusing on innovative solutions for conditions like depression and anxiety.

Financial data not yet available for this company.

Source: [CompaniesByCap](https://companiesbycap.com/company/HELP)